3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Ovarian Neoplasms
11
Prostatic Neoplasms
7
Fallopian Tube Neoplasms
5
Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Glioblastoma
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Prostate Adenocarcinoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Lung Neoplasms
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Glioma
1
Endometrial Neoplasms
1
Disease Progression
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
2
durvalumab
2
Tretinoin
2
Paclitaxel
2
Oxaliplatin
2
Irinotecan
2
Chemoradiotherapy
2
Carboplatin
2
Capecitabine
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
talazoparib
1
sarilumab
1
relugolix
1
pexidartinib
1
pertuzumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
niraparib
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled